This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Atkinson K, Biggs J, Concannon A, Dodds A, Young S, Wilson F et al. A prospective randomised trial of cyclosporin and methotrexate vs cyclosporin, methotrexate and prednisolone for prevention of graft-vs-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. Aust N Z J Med 1991; 21: 850–856.
Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS et al. Equivalence of 2 effective graft-vs-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 2000; 6: 254–261.
Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-vs-host disease: a prospective, randomized trial. Blood 1997; 89: 3880–3887.
Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E . Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-vs-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000; 96: 2391–2398.
Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K et al. What role for prednisone in prevention of acute graft-vs-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037–1045.
Deeg H, Flowers M, Leisenring W, Appelbaum F, Martin P, Storb R . Cyclosporine (CSP) or CSP plus methylprednisolone for graft-vs-host disease prophylaxis in patients with high-risk lymphohemopoietic malignancies: long-term follow-up of a randomized trial. Blood 2000; 96: 1194–1195.
Ruutu T, Volin L, Juvonen E, Parkkali T, Elonen E, Nihtinen A . Cyclosporine, methotrexate and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-vs-host disease in bone marrow transplantation from HLA-identical sibling donor: long-term follow-up of a randomized study (abstract). Bone Marrow Transplant 2003; 31 (Suppl 1): S138.
Sayer HG, Longton G, Bowden R, Pepe M, Storb R . Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-vs-host disease prevention. Blood 1994; 84: 1328–1332.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Quellmann, S., Schwarzer, G., Hübel, K. et al. Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis. Leukemia 22, 1801–1803 (2008). https://doi.org/10.1038/leu.2008.105
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.105